Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Collaboration › Details

Evogene–Leucadia: investor conference, 201908 supply service Evogene presents at Jefferies 2019 Industrials Conference NYC

 

Period Period 2019-08-06 ï¿½ 2019-08-08
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st Evogene Ltd. (Nasdaq, TASE: EVGN)
  Partner, 2nd Jefferies LLC
  Group Leucadia (Group)
Products Product Jefferies 2019 Industrials Conference New York
  Product 2 plant genomics
Persons Person Haviv, Ofer (Evogene 200607 CEO)
  Person 2 Zalik, Nir (Evogene 201907 Investor Relations Director)
     

Evogene Ltd.. (7/15/19). "Press Release: Evogene to Present at Jefferies 2019 Industrials Conference". Rehovot.

Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Ofer Haviv, Evogene’s President and CEO, will present at the Jefferies 2019 Industrials Conference taking place in New York City, August 6-8, 2019. Mr. Haviv’s presentation will focus on the application of Evogene’s technology, the CPB platform, in the area of chemicals and will take place on Wednesday, August 7, at 03:35 pm.

Investors attending the conference who wish to meet with Mr. Haviv, may contact Evogene’s Investor Relations team at ir@evogene.com.


-xxx-


About Evogene:

Evogene (NASDAQ, TASE: EVGN) is a leading biotechnology company developing novel products for major life science markets through the use of a unique computational predictive biology (CPB) platform incorporating deep scientific understandings and advanced computational technologies.

Today, this platform is utilized by the Company to discover and develop innovative products in the following areas (via subsidiaries or divisions): ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, human microbiome based therapeutics and medical cannabis. Each subsidiary or division establishes its product pipeline and go-to-market, as demonstrated in its collaborations with world-leading companies such as BASF, Corteva, Bayer and ICL. For more information, please visit www.evogene.com.


Forward Looking Statements

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene’s control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


Evogene Investor Contact:

Nir Zalik
IR Director
IR@evogene.com
972-8-931-1900

US Investor Relations:

Vivian Cervantes
PCG Investor Relations
vivian@pcgadvisory.com
646-863-6274

   
Record changed: 2019-07-22

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for Evogene Ltd. (Nasdaq, TASE: EVGN)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px




» top